NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential violations of the federal securities laws. If you suffered a loss in Akero securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. ...

NEW YORK, May 22, 2024 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline.SO WHAT: If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

RADNOR, Pa., May 22, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO). The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a ...

Core Viewpoint - A securities class action lawsuit has been filed against Akero Therapeutics, alleging violations of federal securities laws due to misleading statements and omissions regarding the company's business and prospects, resulting in significant investor losses [1][2]. Group 1: Company Overview - Akero Therapeutics is a clinical stage drug development company that has not yet generated any revenues as the FDA has not approved any of its drug candidates for sale [2]. - The company raised over $577 million through two secondary stock offerings and one at-the-market stock offering during the Class Period to finance its operations [2]. Group 2: Class Period and Financial Activities - The Class Period began on September 13, 2022, when Akero reported positive results from its Phase 2b HARMONY study for its lead product candidate, EFX, which is aimed at treating Nonalcoholic steatohepatitis (NASH) [3]. - Following the positive report, Akero conducted a secondary offering, selling over 8.8 million shares at $26 per share, raising approximately $230 million [3]. Group 3: Allegations of Misconduct - Throughout the Class Period, Akero allegedly misled investors about the patient population in its SYMMETRY study, claiming it was limited to patients with NASH-induced cirrhosis, while approximately 20% of the tested patients had not been confirmed to have NASH [4]. - On October 10, 2023, Akero disclosed disappointing interim data from its Phase 2b SYMMETRY trial, revealing that the changes in fibrosis were not statistically significant, leading to a stock price drop of $30.39 per share, or 62.61%, closing at $18.15 [5].

NEW ORLEANS, May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company's shares between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California. ...

RADNOR, Pa., May 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO). The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a re ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Akero and certain of its officers ...

BENSALEM, Pa., May 16, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO).Class Period: September 13, 2022 – October 9, 2023Lead Plaintiff Deadline: June 25, 2024Investors suffering losses on their Akero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (I.R.S. Employer Identification No.) 601 Gateway Boulevard, Suite 350 South San Francisc ...

Exhibit 99.1 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 — — Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second ...